U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06937788) titled 'Replication of the Heads Up Atopic Dermatitis Trial With Registry Data' on April 14.
Brief Summary: The goal is the replication of the primary outcome (EASI 75 at week 16) of the Heads Up trial (Blauvelt, A, Teixeira, H, Simpson, E et al (2021) doi:10.1001/jamadermatol.2021.3023) and the evaluation of the patient reported outcomes (POEM, DLQI and RECAP) in a head-to-head comparison of upadacitinib versus dupilumab treatment in moderate-to-severe atopic dermatitis (AD).
Study Start Date: Aug. 02, 2021
Study Type: OBSERVATIONAL
Condition:
Atopic Dermatitis
Intervention:
DRUG: Upadacitinib
30 mg tablet daily
BIOLOGICAL: Dupilu...